Wednesday, August 15, 2012

Relypsa Gets $80M In Series C

Santa Clara-based Relypsa, a biopharmaceuticals firm focused on polymeric drugs for treating hyperkalemia, said today that it has raised $80M in a Series C funding round. The funding came from OrbiMed Advisors, 5AM Ventures, New Leaf Venture Partners, Sprout Group, Delphi Ventures, Mediphase Venture Partners and new investor Sibling Capital. The firm said the funding will go towards late-stage development, submission of a new drug application (NDA) and commercial planning for its lead product candidate, which is aimed at hyperkalemia, a condition suffered by patients with renal impairment, hypertension, diabetes and heart failure. More information »